Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Other Accumulated Expenses (2019 - 2025)

aTYR PHARMA's Other Accumulated Expenses history spans 7 years, with the latest figure at $844000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 9.75% year-over-year to $844000.0; the TTM value through Dec 2025 reached $844000.0, up 9.75%, while the annual FY2025 figure was $844000.0, 9.75% up from the prior year.
  • Other Accumulated Expenses reached $844000.0 in Q4 2025 per ATYR's latest filing, up from $769000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.9 million in Q4 2022 to a low of $672000.0 in Q4 2021.
  • Average Other Accumulated Expenses over 5 years is $1.1 million, with a median of $844000.0 recorded in 2025.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 187.2% in 2022, then plummeted 43.01% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $672000.0 in 2021, then soared by 187.2% to $1.9 million in 2022, then tumbled by 43.01% to $1.1 million in 2023, then tumbled by 30.09% to $769000.0 in 2024, then grew by 9.75% to $844000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Other Accumulated Expenses are $844000.0 (Q4 2025), $769000.0 (Q4 2024), and $1.1 million (Q4 2023).